VIR's T-cell engagers have potential in oncology and showed promise with initial data in January 2025. Read my thoughts about ...

The programme includes the ECLIPSE 1 and ECLIPSE 2 Phase III trials, aiming to offer registrational data for regulatory ...

After hours: March 11 at 4:32:18 PM EDT Loading Chart for VIR ...

Vir Biotechnology (NASDAQ:VIR – Get Free Report) had its target price increased by equities researchers at Barclays from ...

Vir Biotechnology (NASDAQ:VIR – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC ...

Following the earnings announcement, Vir Biotech's stock rose by 1.74% in after-hours trading, closing at $9.36. [Discover 10 key insights about VIR with an InvestingPro subscription, including ...

Vir Biotechnology (VIR) announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE registrational ...